阿里巴巴赴港上市,上市前一天交易阿里巴巴股票

15th January, 2022
 
有消息称,在线零售商巨头阿里巴巴(Alibaba)要重返香港上市,预计在11月底或12月初上市,拟筹集100亿至150亿美元资金。在过去十年中,阿里巴巴以令人印象深刻的销售和盈利增长而闻名,年增长率超过20%。在本月的11.11 光棍节,仅第一个小时就创造了超过100亿美元的销售额。

值得说的就是,在阿里巴巴赴港上市交易的前一天,您还是可以通过辉立暗盘提前买入阿里巴巴的股票。

 

暗盘交易介绍:

通常暗盘交易都是在新股上市的前一天,不过不是通过交易所的系统,而是通过券商内部的系统进行撮合报价。另外,并不是所有新股都有暗盘,只有在主板上市的新股才有暗盘,在创业板上市的股票,由于发行规则不同,参与的风险比较高,暂时没有接入暗盘交易。关于暗盘价和上市价的关系,尽管暗盘的涨跌从一定程度上体现了新股的受追捧程度,不过暗盘价并不能全面反映市场需求,买卖盘透明度不高,所以暗盘价并不能被视作该股的走势指标。

 

辉立暗盘交易细则

在香港,辉立证券是第一个为客户提供暗盘交易渠道的券商,交易时间一般为新股上市前一个交易日的下午4点15至下午6点半,半日市的交易时间为下午2点15至下午4点半。

了解更多,请访问辉立暗盘交易页面

 

个股举例  – 阅文集团

 

腾讯的子公司阅文与2017年11月8日赴港上市,引发投资者的认购热潮。该股发行价55港币,每手股数为200股,上市前超额认购达625倍。据辉立交易场资料显示,阅文暗盘开市报77.9元,之后高见92元,收报89.65元,较招股价上涨63%。

YUEWENJITUAN

上市首日,阅文开盘报价90港元,后迅速上涨,一度触及110港元,较发行价上涨100%,尽管随后涨幅小幅回落,但一直保持在100港币之上,最后收盘报价102.4港元,上涨近86%,总市值达928亿港元。

 

个股举例  – 希玛眼科
顶着马化腾概念股光环的希玛眼科于2018年1月15日在港交所挂牌。希玛眼科欲募资7300万美元,其中10%的认购者为散户。最终以高达1500倍的超额认购,超越阅文的620倍超额认购。希玛眼科招股书显示,此次IPO将发售1.97亿股股份,其中香港发售1970万股,国际发售1.773亿股,发售股份将占公司全球发售完成后的已发行股本的25.05%,价格在2.35-2.9港元之间,每手2000股。

XIMAYANKE
在创下史上最高超额认购记录后,前一交易日的暗盘交易也极为火爆。根据辉立证券香港官网数据显示,希玛眼科交易价达4.97港元,较招股价大涨71%。总成交额超过1.2亿港元。

 

上市当日,该股开盘即暴涨84.5%,报5.35港元。之后股价如坐火箭一般飙升,连续4日大幅上涨,最高价达19.9港元,较发行价涨686.2%,较第一天开盘价涨371.96%。之后有所回落。

 

 

 

 
关键字:新加坡股票研报,新加坡股,新加坡研报,新加坡房地产, 新加坡账户,交易新加坡股票,新加坡股票开户,免费开户,在线开设新加坡股票开户,新加坡证券,新加坡券商,投资组合,IPO, 香港IPO, 阿里巴巴IPO

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com